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The endothelin-type-A receptor in dilated cardiomyopathy:
another key player?
See page 1948 for the article to which this Editorial
refers
Chronic impairment of left ventricular function
activates various homeostatic mechanisms. Most of
them are vasoconstrictor, positive chronotropic and
inotropic stimuli which aim at maintaining adequate
cardiac output and organ perfusion. Ultimately, how-
ever, they have adverse eﬀects on the cardiovascular
system and contribute significantly to the process of
cardiovascular remodelling and, thereby, morbidity
and mortality. Importantly, strategies to remove the
adverse influence of an activated renin-angiotensin-
aldosterone and sympathetic nervous system by treat-
ment with angiotensin converting enzyme inhibitors[1],
the aldosterone antagonist spironolactone[2], and
beta-blockers[3] have proven extremely successful.
In recent years, the endothelium has been recog-
nised as a source of potent vasoactive substances,
among them the vasoconstrictor peptide endothelin-1
(ET-1)[4]. ET-1 is one of the most potent and long
lasting vasoconstrictors known. In addition, ET-1 is
an important growth promoter[5].
The eﬀects of ET-1 are mediated by two distinct
receptors: the ET-1 selective ET and the non-
isopeptide-selective ET receptor. The vasoconstric-
tor eﬀects of ET-1 are predominantly mediated by
ET receptors; however, vascular smooth muscle cells
also express ET receptors which contribute to ET-1
mediated vasoconstriction. ET receptors also exist
on endothelial cells and modulate the vasoconstrictor
eﬀects of ET-1 through generation of nitric oxide
and/or prostacyclin. Moreover, adrenal ET-1 recep-
tors mediate release of aldosterone and ET receptors
on renal tubuli mediate diuresis and natriuresis in
dogs. While the majority of functional ET-1 receptors
in cardiac myocytes, particularly in failing myocar-
dium, are of the ET type and myocyte growth,
accordingly, is an ET- receptor mediated process,
fibroblasts contain both ET and ET receptors.
Thus, collagen synthesis seems to be mediated
through both ET and ET receptors. In addition, the
ET receptors serve as clearance receptors for ET-1
from the circulation (for review[6]).
Several lines of evidence suggest that the endothelin
system plays an important role in human heart failure
(for review[7]). Thus, plasma ET-1 levels are increased
in more severely symptomatic patients with heart
failure and the extent of haemodynamic impairment
is closely related to plasma ET-1 levels. The main
source of elevated ET-1 in heart failure appears to be
the pulmonary circulation and elevated levels corre-
late well with pulmonary vascular tone and pulmon-
ary hypertension. Elevated angiotensin II and
norepinephrine levels in heart failure also
increase ET-1 production and release. While endog-
enous ET-1 has a positive inotropic eﬀect in normal
myocardium it has a negative inotropic eﬀect in the
failing myocardium of patients with dilated cardio-
myopathy. ET-1 plasma levels correlate inversely
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with exercise capacity, suggesting a role in the
reduced peripheral perfusion characteristic of heart
failure. Importantly, elevated ET-1 and big ET-1
levels are strong and independent predictors for patient
survival. In addition, blocking ET-1 eﬀects by ET-1
receptor antagonists caused haemodynamic improve-
ment in patients with heart failure[8] and improved
survival in rats with heart failure induced by a large
myocardial infarction[9,10], i.e. in the model that pre-
dicted the clinical eﬀects of ACE-inhibitors. Finally, it
was shown that a polymorphism of the ET receptor
gene on exon 8 (+1363 C/T) was associated with
non-ischaemic dilated cardiomyopathy with a signifi-
cant increase in the number of T/T homozygotes among
patients, particularly in younger subjects in whom gen-
etic factors are expected to be of importance[11]. Thus, a
multitude of data suggest that the endothelin system is
intricately involved in the pathophysiology of human
heart failure and removing its influence on the cardio-
vascular system may prove beneficial.
It is against this background that the data reported
in this issue by Herrmann and colleagues[12] are of
special interest. They found that a genetic variant
of the ET receptor, e.g. the H323H (H/T) poly-
morphism in exon 6 of the ET receptor gene, had a
marked and significant influence on survival in a
cohort of patients with non-ischaemic dilated
cardiomyopathy. Carriers of the less frequent ET
receptor T allele had a more than fivefold increased
risk of dying within 2 years after presenting with the
diagnosis and this eﬀect was independent from other
predictors of survival in such patients. In contrast,
five other polymorphisms of the ET-1 gene, the ET
and the ET receptor had no influence on survival.
An association of a genetic variant with survival
in patients with heart failure has been noted before
and the data resemble those found for another key
cardiovascular signalling element in heart failure, e.g.
the Ile164 2-adrenoceptor polymorphism which was
also associated with poor survival in patients with
chronic heart failure[13]. What conclusions can be
drawn from findings like these? Obviously, the possi-
bility of using the presence of such a genetic variant
for risk assessment in patients appears attractive.
Theoretically, patients carrying the T allele might be
candidates for earlier aggressive interventions includ-
ing transplantation. It is also conceivable that the
presence of this genetic variant might influence the
response to ET-1 receptor antagonists if these com-
pounds are to be used therapeutically in heart failure
patients in the future. However, before accepting
these contentions one must recall that each individual
carries a library of genetic polymorphisms, most of
which are irrelevant for the disease in question. Thus,
certain criteria should be met before a genetic change
can be linked with a disease trait. Firstly, the poly-
morphism should result in an alteration of the gene
product. Secondly, the relationship between the gen-
etic alteration and the corresponding phenotype
should be strong, and, thirdly, the association must
be biologically plausible.
Based upon the evidence presented earlier, there is
no major objection to the biological plausibility of the
reported association. How about the other criteria?
As the authors note, the H323H (H/T) polymorphism
in exon 6 of the ET receptor gene does not change
the amino acid sequence of the receptor. Functional
studies of this variant are not available but it is likely
that receptor function is not altered unless this vari-
ant influences gene transcription or creates a novel
splice site. Alternatively, as the authors suggest,
this finding could mean that this polymorphism
co-segregates with another functionally active but so
far unidentified genetic variant and, therefore, acts as
a marker for some other deleterious trait. As for the
association between the genetic variant and the
phenotype, the data appears fairly strong with a risk
ratio for death of 5·5 for carriers of the ET T allele.
However, the number of deaths on which the analysis
is based is small and the lower 95% confidence
interval barely does not include 1. Moreover, the
study may be criticized from a statistical point of view
as the authors examined six polymorphisms. Thus,
based on multiple testing and a 5% chance for each
test to yield a false positive result, there was a chance
of up to 30% for a false positive finding. Finally,
although the authors could demonstrate that haemo-
dynamic and structural cardiac changes had no
impact on the strength of this association they did not
investigate other well proven markers of survival
in heart failure patients such as plasma levels of
natriuretic peptides, and ET-1 and big ET-1. It is
obvious that the relationship between activation
of the endothelic-1 system and this genetic poly-
morphism would have been of particular interest.
Taken together, it appears that the reported
association of this genetic variant and survival in
patients with non-ischaemic dilated cardiomyopathy
is intriguing but can by no means be considered to be
proven. Interestingly, the (G+70C) polymorphism of
the ET receptor gene had no influence on survival
in this study. This variant is in close linkage dis-
equilibrium with the (+1363 C/T) variant on exon 8
of the ET receptor gene, the T/T variant of which
was more frequently found in patients with dilated
cardiomyopathy than in control subjects[11]. Whether
this indicates that some ET receptor gene variants
are involved in the development of the phenotype, i.e.
non-ischaemic dilated cardiomyopathy, and others,
like the currently investigated variant, which are
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important for the development of disease compli-
cations, is an attractive but clearly unproven
hypothesis.
Where will findings like these lead us? Certainly,
additional studies will follow and it is to be hoped
that a reasonably clear picture of the influence of
genetic variants of the endothelin system on the
development of the disease and its complications will
emerge. This does not necessarily have to be the case,
as shown for another well publicized genetic poly-
morphism in cardiovascular diseases, namely the
insertion (I)/deletion (D) polymorphism of the angio-
tensin converting enzyme gene. After many early
positive reports about the association of the DD
variant with a variety of cardiovascular disorders,
among them myocardial infarction, hypertension,
and left ventricular hypertrophy subsequent studies
in additional populations have been frequently
inconsistent (for review[14]). Also, it emphasizes our
incomplete understanding of the interaction of
genetic changes with disease phenotypes. The other
genetic variant associated with poor survival in heart
failure, e.g. the Ile1642-adrenoceptor polymorphism,
results in a loss of receptor function[15]. This makes
understanding the beneficial clinical eﬀects of phar-
macologically induced loss of function, e.g. beta-
blocker therapy, somewhat diﬃcult. Thus, future
research will not only have to show that this genetic
variant of the ET receptor gene truly influences
survival, but should also provide meaningful insights
into the mechanisms whereby genetic factors
interact with the development of heart failure and its
complications.
W. KIOWSKI
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